DT07 Rec'd PCT/PTO 0 7 JUL 2004

		- -		<u> </u>								
FORM I	PTO-139	90 (Modified) • U.S. DEPARTMENT O	F COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER								
(JCLV.	TI	RANSMITTAL LETT	ER TO THE UNITED STATES	255062US0PCT								
		DESIGNATED/ELE	CTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR								
			LING UNDER 35 U.S.C. 371	10/500891								
INTE		IONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
		PCT/FR03/00129	16 JANUARY 2003	18 JANUARY 2002								
PHC	SPH		E DERIVATIVES FOR THE SELECTIV N I CONVERTING ENZYME (ACE)	E INHIBITION OF THE C-TERMINAL								
		T(S) FOR DO/EO/US										
		TON, et al.										
Appli	cant l	herewith submits to the United	d States Designated/Elected Office (DO/EO/US)	the following items and other information:								
1.	×		of items concerning a filing under 35 U.S.C. 37									
2.			SEQUENT submission of items concerning a fi									
3.	Ø			_								
		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.										
4.	\boxtimes	The US has been elected by	the expiration of 19 months from the priority da	ate (Article 31).								
5.	\boxtimes	A copy of the International	Application as filed (35 U.S.C. 371 (c) (2))									
			required only if not communicated by the Inter	national Bureau).								
			cated by the International Bureau.									
		c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).										
6.	\boxtimes	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).										
		a. 🛛 is attached hereto.										
		b. has been previously submitted under 35 U.S.C. 154(d)(4).										
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. are attached hereto (required only if not communicated by the International Bureau).										
				rnational Bureau).								
		 b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. 										
				idments has NOT expired.								
	_		e and will not be made.	C. A. C. L. 10 (25 H.O.C. 271()(2))								
8. 0			tion of the amendments to the claims under PC7	Article 19 (35 U.S.C. 371(c)(3)).								
9. 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT										
l	_	Article 36 (35 U.S.C. 371 (c	, , ,									
11.	□ 627	A copy of the International Preliminary Examination Report (PCT/IPEA/409). A copy of the International Search Report (PCT/ISA/210).										
12.	×											
			ment(s) or information included:									
13.			Statement under 37 CFR 1.97 and 1.98.									
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
15.	\boxtimes	A FIRST preliminary amendment.										
16. 17.		A SECOND or SUBSEQUENT preliminary amendment.										
18.		A substitute specification.										
19.		A change of power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.										
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).										
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).										
22.		Express Mail Label No.										
23.	\boxtimes	Other items or information:										
		Application Data Sheet Notice of Priority	Request for Consideration of Documents Cit Drawings (3 Sheets)	ted in International Search Report								
		PCT/IB/304 PCT/IR/308										

U.S. APPLICATION NO. (IF KNOWN, SEE 378F9 1 INTERNATIONAL APPLICATION NO. PCT/FR03/00129								ATTORNEY'S DOCKET NUMB 255062US0PCT			
24.	The fol	lowing fees are subn	nitted:.					CAL	CULATION	S PTO USE ONLY	
		L FEE (37 CFR 1.4									
	international	search fee (37 CFR	1.445(a)(2))	fee (37 CFR 1.482) r paid to USPTO by the EPO or JPO			\$1080.00	:			
⊠	 ✓ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO										
	Internationa but internati	l preliminary examin onal search fee (37 C	ation fee (37 CFR 1.445(a)(CFR 1.482) not paid (2)) paid to USPTO.	to USPTC) 	\$770.00				
	but all claim	s did not satisfy prov	visions of PC	CFR 1.482) paid to U Γ Article 33(1)-(4)			\$730.00				
	Internationa and all clain	s satisfied provision	s of PCT Arti	CFR 1.482) paid to Ucle 33(1)-(4)			\$100.00				
		ENTER AP	PROPRIA	ATE BASIC FE	EE AMO	OUI	YT =		\$920.00		
Surcha month	arge of \$130.0 s from the ear	0 for furnishing the liest claimed priority	date (37 CF	R 1.492 (e)).		0	□ 30		\$0.00		
CL	AIMS	NUMBER I	FILED	NUMBER EXT	ΓRA		RATE	ļ			
Total o	laims	24	- 20 =	4		х	\$18.00		\$72.00		
Indepe	ndent claims	8	- 3 =	5		х	\$86.00	ļ	\$430.00		
Multip	le Dependent	Claims (check if ap	 						\$0.00		
				ABOVE CALO			<u>NS = </u>		\$1,422.00		
	applicant clair educed by 1/2		s. See 37 CFR	1.27. The fees indicate	ated above	are			\$0.00		
					SUB	<u>ΓΟ</u>]	$\Gamma AL =$		\$1,422.00		
Proces month	sing fee of \$1 s from the ear	30.00 for furnishing liest claimed priority	the English to date (37 CF	ranslation later than R 1.492 (f)).	□ 20	0	□ 30 +		\$0.00		
				TOTAL NAT	IONAI	FI	E E =		\$1,422.00		
Fee for	r recording th panied by an	e enclosed assignment appropriate cover sho	nt (37 CFR 1 eet (37 CFR 3	21(h)). The assignm 3.28, 3.31) (check if	ent must b	e).			\$0.00		
				TOTAL FEES	ENCL	OS]	ED =		\$1,422.00		
								Amou	int to be: efunded	\$	
									harged	\$	
a.	☐ A ch	eck in the amount of	 f	to cover the	above fees	s is e	nclosed.				
Ъ.	_	se charge my Deposi			in the ame				to cover t	he above fees.	
c.		Director is hereby au	uthorized to c	harge any additional				, or cred	dit any overpa	yment	
	to D	eposit Account No.	15-0030								
d.		_		WARNING: Inform on this form. Provide			•	•			
				CFR 1.494 or 1.495 the application to p			net, a petitio	on to re	evive (37 CFR	t	
SEND	ALL CORRI	ESPONDENCE TO:						1			
	hone No.: 7		C	inder Sachar	1	_	fru	wh	Sacha	1	
Fax N	No.: 703-413 omer Number	-2220		ation No. 34,4	23		SNATURE				
	Norman F. On							oion	_		
						NA	ME				
						24	,618		<u></u>		
						RE	GISTRATIC	טא אט	MBER		
							TE	JUly	7 700	4	
						J.					

Docket No.

255062US0P

IN RE APPLICATION OF: Joel COTTON, et al.

SERIAL NO: NEW U.S. PCT APPLICATION (based on PCT/FR03/00129)

FILED:

HEREWITH

FOR:

PHOSPHINIC PSEUDOPEPTIDE DERIVATIVES FOR THE SELECTIVE INHIBITION OF THE C-TERMINAL

ACTIVE SITE OF ANGIOTENSIN I CONVERTING ENZYME (ACE)

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

CI	m	

Transmitted herewith is an amendment in the above-identified application.

- ☐ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- Additional documents filed herewith:

English translation of Specification/Declaration/Application Data Sheet Notice of Priority/Credit Card Payment Form for \$1422.00/Drawings (3 Sheets)

PCT Transmittal Letter/Preliminary Amendment/PCT/IB/304/PCT/IB/308

International Search Report/Request for Consideration

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE			CALCULATIONS	
TOTAL	24	MINUS	24	0	х	\$18	=	\$0.00	
INDEPENDENT	8	MINUS	8	0	х	\$86	=	\$0.00	
		☐ MULTIPLE DEPENDENT CLAIMS				\$290	=	\$0.00	
		TOTAL OF ABOVE CALCULATIONS \$0.00							
		☐ Reduction by 50% for filing by Small Entity					\$0.00		
		☐ Recordation of Assignment				\$40	=	\$0.00	
TOTAL							\$0.00		

	Α	chec	k in	the	amount	of	` <u>\$0.00</u>	_is	attac	hed	l.
--	---	------	------	-----	--------	----	-----------------	-----	-------	-----	----

- ☐ Credit card payment form is attached to cover the fees in the amount of \$0.00
- Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☑ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Surinder Sachar

Registration No. 34,423

DOCKET NO.: 255062US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Joel COTTON, et al. SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/FR03/00129

INTERNATIONAL FILING DATE: January 16, 2003

FOR: PHOSPHINIC PSEUDOPEPTIDE DERIVATIVES FOR THE SELECTIVE INHIBITION OF

THE C-TERMINAL ACTIVE SITE OF ANGIOTENSIN I CONVERTING ENZYME (ACE)

REQUEST FOR CONSIDERATION OF DOCUMENTS CITED IN INTERNATIONAL SEARCH REPORT

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that applicant(s) request that the Examiner consider the documents cited in the International Search Report according to MPEP §609 and so indicate by a statement in the first Office Action that the information has been considered. When the Form PCT/DO/EO/903 indicates both the search report and copies of the documents are present in the national stage file, there is no requirement for the applicant(s) to submit them (1156 O.G. 91 November 23, 1993).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618

Surinder Sachar

Registration No. 34.4

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)